Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...5253545556575859606162...208209»
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  SHR0302 and Steroid As First Line Therapy for Chronic GVHD (clinicaltrials.gov) -  Nov 13, 2024   
    P1,  N=28, Completed, 
    In this trial, the combination of camrelizumab, apatinib, and capecitabine showed promising antitumor activity and manageable toxicity in patients with advanced BTC, especially in the first-line setting. Recruiting --> Completed | N=73 --> 28 | Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Sep 2024
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date:  A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma (clinicaltrials.gov) -  Nov 12, 2024   
    P2,  N=0, Withdrawn, 
    Not yet recruiting --> Recruiting N=16 --> 0 | Trial completion date: Nov 2028 --> Nov 2024 | Initiation date: Apr 2025 --> Nov 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2026 --> Nov 2024
  • ||||||||||  Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia (clinicaltrials.gov) -  Nov 7, 2024   
    P3,  N=240, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2024 --> Jul 2024
  • ||||||||||  zeprumetostat (SHR-2554) / Treeline Biosci, retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
    New P2 trial:  SHR-1701 Combined with SHR2554 and BP102 for MCRC (clinicaltrials.gov) -  Nov 6, 2024   
    P2,  N=20, Not yet recruiting, 
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeOne Medicines, Keytruda (pembrolizumab) / Merck (MSD), AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial initiation date, Checkpoint inhibition, IO biomarker:  ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI (clinicaltrials.gov) -  Nov 6, 2024   
    P2,  N=27, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2024 --> Jul 2024 Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Aug 2024
  • ||||||||||  recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
    Clinical, P3 data, Journal, Monotherapy:  Recaticimab Monotherapy for Nonfamilial (Pubmed Central) -  Nov 6, 2024   
    Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Aug 2024 Recaticimab monotherapy yielded significant LDL-C reductions and showed comparable safety vs placebo in patients with nonfamilial hypercholesterolemia and mixed hyperlipemia at low-to-moderate ASCVD risk, even
  • ||||||||||  Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_5999;    
    TAs included BRAF inhibitor (vemurafenib [1]), MEK inhibitors (binimetinib [1], cobimetinib [2], trametinib [2]) and others (dasatinib [1], pazopanib [1], pexidartinib [1]), while ICIs were exclusively pembrolizumab (5)...TAs included BRAF inhibitor only (vemurafenib [3], dabrafenib [3]), MEK inhibitor only (trametinib [5]), BRAF + MEK inhibitors (2), and others (apatinib, anlotimib, bevacizumab, daratumumab, dasatinib, imatinib, pazopanib, sorafenib, or combinations [9]), while ICIs included pembrolizumab (4), nivolumab (4), tislelizumab (1), and sintilimab (1)...Conclusion TAs and ICIs can be considered in the management of MH. The responses to ICI therapy may be associated with the degree of PDL1 expression
  • ||||||||||  Koselugo (selumetinib) / Merck (MSD), AstraZeneca, plinabulin (BPI 2358) / BeyondSpring
    Plinabulin and Selumetinib Enhance M1 Macrophage Traits and Trigger Cell Death in AML (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_5292;    
    Additionally, both drugs were associated with reduced mitochondrial membrane potential in leukemic blasts and AAMs, suggesting an impact on mitochondrial metabolism. In conclusion, we found that both BPI-2358 and AZD6244 exhibit potential in repolarizing M2-like TAMs towards an M1-like phenotype, and have cytotoxic activity in AAM and leukemic blasts thus representing a promising avenue for enhancing AML treatment strategies.
  • ||||||||||  Itari (linperlisib) / Shanghai YingLi Pharma
    Phosphorylation-Dependent ANXA2 Relocation on the Membrane and TLR4 Engagement: A Novel Signaling Axis Promoted By PIM1 Mutation in Diffuse Large B Cell Lymphoma (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_4895;    
    Notably, the PIM1 inhibitor SMI-4a demonstrated synergistic antitumor effects with the PI3K inhibitor Linperlisib in vitro and in vivo, offering a potentially more effective therapeutic strategy for patients harboring PIM1 mutations. Conclusions : Taken together, we identify recurrent somatic PIM1 L184F mutations that may contribute to the pathogenesis of DLBCL and establish the rationale for therapeutic strategies aimed at targeting the oncogenic pathway activated in PIM1-mutated DLBCL.
  • ||||||||||  Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
    Hetrombopag, an Emerging Iron-Chelating Agent, Alleviates Systemic Iron Overload (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_4776;    
    Furthermore, compared with those in DFX-treated mice, immune response-related signalling pathways, especially those related to the inhibition of the response to type I interferon, were significantly enriched in HPAG-treated mice. Conclusion : HPAG is an emerging iron-chelating agent and a potential inhibitor of ferroptosis that alleviates tissue damage, haematopoietic stem cell injury, and immune abnormalities caused by systemic iron overload and provides an immunoregulatory function.